Navigation Links
Antiviral drugs may slow Alzheimer's progression
Date:10/17/2011

Antiviral drugs used to target the herpes virus could be effective at slowing the progression of Alzheimer's disease (AD), a new study shows.

The University of Manchester scientists have previously shown that the herpes simplex virus type 1 (HSV1) is a risk factor for Alzheimer's when it is present in the brains of people who have a specific genetic risk to the disease.

AD is an incurable neurodegenerative condition affecting about 18 million people worldwide. The causes of the disease or of the abnormal protein structures seen in AD brains amyloid plaques and neurofibrillary tangles are completely unknown.

The Manchester team has established that the herpes virus causes accumulation of two key AD proteins β-amyloid (Aβ) and abnormally phosphorylated tau (P-tau) known to be the main components of plaques and tangles respectively. Both proteins are thought by many scientists to be involved in the development of the disease.

"We have found that the viral DNA in AD brains is very specifically located within amyloid plaques," said Professor Ruth Itzhaki, who led the team in the University's Faculty of Life Sciences. "This, together with the production of amyloid that the virus induces, suggests that HSV1 is a cause of toxic amyloid products and of plaques.

"Our results suggest that HSV1, together with the host genetic factor, is a major risk for AD, and that antiviral agents might be used for treating patients to slow disease progression."

Currently available antiviral agents act by targeting replication of HSV1 DNA, and so the researchers considered that they might be successful in treating AD only if the accumulation of β-amyloid and P-tau accumulation caused by the virus occurs at or after the stage at which viral DNA replication occurs.

"If these proteins are produced independently of HSV1 replication, antivirals might not be effective," said Professor Itzhaki. "We investigated this and found that treatment of HSV1-infected cells with acyclovir, the most commonly used antiviral agent, and also with two other antivirals, did indeed decrease the accumulation of β-amyloid and P-tau, as well as decreasing HSV1 replication as we would expect.

"This is the first study investigating antiviral effects on AD-like changes and we conclude that since antiviral agents reduce greatly β-amyloid and P-tau levels in HSV1-infected cells, they would be suitable for treating Alzheimer's disease. The great advantage over current AD therapies is that acyclovir would target only the virus, not the host cell or normal uninfected cells. Further, these agents are very safe and are relatively inexpensive.

"Also, by targeting a cause of Alzheimer's disease, other viral damage, besides β-amyloid and P-tau, which might be involved in the disease's pathogenesis, would also be inhibited.

"The next stage of our research subject to funding will focus on finding the most suitable antiviral agent or combination of two agents that operate via different mechanisms for use as treatment. We then need to investigate the way in which the virus and the genetic risk factor interact to cause the disease, as that might lead to further novel treatments.

"Eventually, we hope to begin clinical trials in humans but this is still some way off yet and again will require new funding."

The study, carried out with Dr Matthew Wozniak and other colleagues in the Faculty of Life Sciences, is published in the Public Library of Science (PLoS) One journal.


'/>"/>

Contact: Aeron Haworth
aeron.haworth@manchester.ac.uk
44-161-275-8383
University of Manchester
Source:Eurekalert

Related medicine news :

1. UC Irvine study points to new approach to influenzas antiviral resistance
2. Arrival of direct antiviral agent therapy for hepatitis C sparks debate of who to treat first
3. Lack of health insurance limits hepatitis C patients access to latest antiviral therapy
4. New antiviral drug shows promise for dramatic improvement in hepatitis C treatment
5. Longer Antiviral Therapy Reduces Lung Transplant Complications
6. Antiviral therapy during compensated cirrhosis most cost-effective approach
7. New Study: Improved Immune System with Gene-Eden, a Natural Antiviral Supplement that Targets Chronic Viruses
8. Tests to catch the makers of dangerous legal high designer drugs
9. $8.4 million grant supports health information exchange and research on Alzheimers drugs
10. Mushroom compound appears to improve effectiveness of cancer drugs
11. Study uncovers why anti-rejection drugs for transplant patients cause hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... Intellitec Solutions is ... of Microsoft Dynamics GP for one their long-term care clients. Working together with ... GP with key clinical management systems, and delivered a fully integrated accounting and ...
(Date:4/29/2016)... ... April 29, 2016 , ... Pro3rd Grunge is a package of 30 grunge-themed ... to introduce people, characters, and locations without having to set a single keyframe. Choose ... many more design components. Simply select a preset and drag it into the ...
(Date:4/29/2016)... ... April 29, 2016 , ... In its efforts of bringing quality ... its successful franchise development and expansion as it welcomes Ferdie Vasquez of the new ... experience in his 32 years of working in various industries. He had been ...
(Date:4/28/2016)... St. Petersburg, FL (PRWEB) , ... April 29, 2016 , ... Sublime Beauty® is offering ... of the same product) for 50% off. The discount is applied to the product with ... box is given to those who purchase $250 or more in products. , "So many ...
(Date:4/28/2016)... ... 28, 2016 , ... ProText Layouts is a set of 30 self-animating kinetic ... With ProText Layouts, video editors can create an energetic typography video with incredible ease. ... texts. Creating text-based videos have never been easier. , ProText Layouts includes 30 ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 , Net Sales of $1.90 ... over the prior year period, and an increase of 1.2% ... Diluted EPS for the first quarter were $0.52 reported, a ... adjusted, an increase of 29.9% over the prior year period ... earnings guidance for 2016 Zimmer Biomet Holdings, Inc. ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology: